Benzinga's Microcap Movers for Monday August 6, 2012

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves: DiMi Telematics International Shares of DiMi Telematics International (DIMI), the New York City-based developer of cloud-based Machine-to-Machine communications solutions, rose 54.84% Monday on higher than average volume. A newsletter last Thursday mentioned more than 100% of the float was short on DiMi Telematics. DiMi Telematics International closed at $0.12 on Monday. Cytomedix Shares of Cytomedix (CMXI), the Gaithersburg, MD biotechnology company, rose 30.16% Monday on 3 times average, volume. Cytomedix announced Monday that the Centers for Medicare & Medicaid Services has issued a final National Coverage Determination for autologous blood-derived products for chronic non-healing wounds. As previously reported, on May 9, 2012 CMS posted its proposed NCD, which was followed by a 30-day public comment period that ended on June 8th. In the final decision memo released August 2nd, CMS responded to these comments, refined its decision and confirmed coverage for autologous platelet rich plasma in patients with diabetic, pressure and/or venous wounds via its Coverage with Evidence Development program. CED is a process through which CMS provides reimbursement coverage for items and services while generating additional clinical data to demonstrate their impact on health outcomes. Cytomedix closed at $1.64 on Monday. OXiGENE Shares of OXiGENE OXGN, the Rochester, NY supplier of advanced network communications solutions, rose 17.65% Monday on 5 times average volume. OXiGENE announced Monday that the randomized Phase 2 study evaluating the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and bevacizumab to treat patients with advanced platinum-sensitive ovarian cancer has achieved an important safety objective in a scheduled interim toxicity analysis, and is expected to continue to full enrollment. The Phase 2 study (GOG 186I) is being conducted by the Gynecologic Oncology Group (GOG) under the sponsorship of the Cancer Therapy Evaluation Program of the National Cancer Institute. The fosbretabulin tromethamine is being provided to CTEP under a Cooperative Research and Development Agreement with OXiGENE and the bevacizumab is being provided under a CRADA with Genentech, Inc. OXiGENE closed at $0.60 on Monday. The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.